immunocore-logo-2018
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
September 09, 2022 10:00 ET | Immunocore Holdings Limited
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3...
immunocore-logo-2018
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
August 03, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...
immunocore-logo-2018
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
June 25, 2022 04:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
immunocore-logo-2018
Immunocore Appoints Siddharth Kaul to its Board of Directors
June 09, 2022 07:45 ET | Immunocore Holdings Limited
Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR)...
immunocore-logo-2018
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
June 08, 2022 07:00 ET | Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
immunocore-logo-2018
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...
immunocore-logo-2018
Immunocore to present at the 21st Annual Needham Healthcare Conference
April 07, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 21st Annual Needham Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 7 April 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
immunocore-logo-2018
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
April 04, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...
immunocore-logo-2018
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
March 09, 2022 17:30 ET | Immunocore Holdings Limited
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq:...
immunocore-logo-2018
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
March 03, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...